For the second quarter of its FY2023, CATALYST PHARMACEUTICALS ($NASDAQ:CPRX) reported a total revenue of USD 99.6 million, a year-over-year growth of 87.5%, as well as a net income of USD 37.8 million, representing a 74.7% increase from the same period in the prior year.
On Wednesday, CATALYST PHARMACEUTICALS reported their Q2 earnings results for the fiscal year of 2023. The stock opened at $14.3 and closed at $14.1, indicating a decrease of 1.5% from the previous closing price of 14.3. Going forward, investors will be keeping a close eye on the company to see if it can continue to meet or exceed its earnings targets in upcoming quarters. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Catalyst Pharmaceuticals. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Catalyst Pharmaceuticals. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Catalyst Pharmaceuticals. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Catalyst Pharmaceuticals are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Catalyst Pharmaceuticals Intrinsic Stock Value
At GoodWhale, we recently conducted an analysis of CATALYST PHARMACEUTICALS‘s wellbeing. Through our proprietary Valuation Line, we have calculated the intrinsic value of CATALYST PHARMACEUTICALS share to be around $13.9. However, at present, the stock is trading at $14.1, representing a fair price that is slightly overvalued by 1.4%. More…
Risk Rating Analysis
Star Chart Analysis
The pharmaceutical industry is intensely competitive, with companies vying for market share of both existing drugs and new drugs under development. Catalyst Pharmaceuticals Inc is no exception, competing against other pharmaceutical companies such as Gossamer Bio Inc, uniQure NV, and Spero Therapeutics Inc. In order to maintain or grow its market share, Catalyst must continually develop new and innovative drugs and market them effectively.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The company’s market cap is $940.04M as of 2022 and its ROE is -672.28%. The company’s products include GB001, GB002 and GB004. GB001 is a phase 1 clinical trial product for the treatment of ulcerative colitis. GB002 is a phase 2 clinical trial product for the treatment of Crohn’s disease. GB004 is a phase 2 clinical trial product for the treatment of non-small cell lung cancer.
uniQure NV is a Dutch biotech company that focuses on the development and commercialization of gene therapies. As of 2022, the company has a market cap of 867.48M and a ROE of -12.84%. The company’s main products are Glybera and Amryt Pharma. Glybera is a gene therapy treatment for lipoprotein lipase deficiency, while Amryt Pharma is a treatment for epidermolysis bullosa.
– Spero Therapeutics Inc ($NASDAQ:SPRO)
Spero Therapeutics Inc is a pharmaceutical company that focuses on the development of treatments for rare and infectious diseases. The company has a market cap of $66.98 million and a return on equity of -138.12%. The company’s products include treatments for bacterial infections, fungal infections, and viral infections.
Catalyst Pharmaceuticals reported strong financial results for the second quarter of its FY2023, with total revenue of USD 99.6 million and net income of USD 37.8 million, representing year-over-year increases of 87.5% and 74.7%, respectively. This indicates a positive outlook for investors looking to invest in the company’s stocks. Further analysis of Catalyst’s financials reveals healthy balance sheets and cash flows, which provide good foundations for future growth.
Additionally, the company’s trend of consistent revenue growth and profitability demonstrate Catalyst’s potential to generate attractive returns on investment. Therefore, investors should consider investing in Catalyst Pharmaceuticals, as it is well-positioned to continue delivering strong financial results in the foreseeable future.